BACKGROUND: Panel testing has been recently introduced to evaluate hereditary cancer; however, limited information is available regarding its use in kidney cancer. METHODS: The authors retrospectively reviewed test results and clinical data from patients who underwent targeted multigene panel testing of up to 19 genes associated with hereditary kidney cancer from 2013 to 2016. The frequency of positive (mutation/variant likely pathogenic), inconclusive (variant of unknown significance), and negative results was evaluated. A logistic regression analysis evaluated predictive factors for a positive test. RESULTS: Patients (n 5 1235) had a median age at diagnosis of 46 years, which was significantly younger than the US population of individuals with kidney cancer (P <.0001). Overall, 6.1%, 75.5%, and 18.4% of individuals had positive, negative, and inconclusive results, respectively. The most commonly altered genes included folliculin (FLCN) and fumarate hydratase (FH), which were altered in 1.8% and 1.3% of patients, respectively. Tuberous Sclerosis Complex 2 (TSC2), mesenchymal epithelial transition factor proto-oncogene (MET), and PMS1 homolog 2 (PMS2) had the highest rates of variants of unknown significance, which were identified in 2.7%, 2.2%, and 1.7% of patients, respectively. Early age of onset was the only factor that was identified as predictive of a positive test on multivariate analysis (odds ratio, 0.975; P 5.0052) and may be the only identifying characteristic of low-penetrant syndromes, such as those associated with MITF (melanogenesis-associated transcription factor) mutations, which do not have singular histology or a family history of kidney cancer. CONCLUSIONS: Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes. The current results support the use of early age of onset for genetic counseling and/or testing.
INTRODUCTION
It is believed that from 5% to 8% of kidney cancers are associated with a heritable condition; however, this is likely a conservative estimate. 1 Population-based studies have demonstrated that up to 58% of patients with renal cell carcinomas (RCCs) may be linked to a hereditary predisposition. 2 Multiple hereditary kidney cancer syndromes have been characterized, such as von Hippel-Lindau (VHL), hereditary papillary renal cell carcinoma (HPRC), Birt-Hogg-Dube syndrome, hereditary leiomyomatosis and RCC, tuberous sclerosis complex (TSC), and Cowden syndrome, each of which has been associated with germline mutations in VHL, mesenchymal epithelial transition factor proto-oncogene (MET), folliculin (FLCN), fumarate hydratase (FH), tuberous sclerosis 1/2 (TSC1/TSC2), and phosphatase and tensin homolog (PTEN), respectively. 3 The treating physician is responsible for recognizing patients who may benefit from genetic counseling and testing. Referral may be straightforward for those with bilateral, multifocal renal masses; a personal/family history of other primary malignancies; and/or skin manifestations suggestive of a specific syndrome. Recognition of well known syndromes often requires a comprehensive evaluation, which may initially present as a simple case of RCC to a specialist unfamiliar with subtle manifestations. In addition, recently described syndromes, such as those associated with melanogenesis-associated transcription factor (MITF) and BRCA1 associated protein 1 (BAP1), may be more subtle because of reduced disease penetrance. Referral of individuals with an early onset kidney cancer (aged 46 years) for genetic counseling has been proposed as a guideline to aid in the identification of at-risk patients. 1 The American College of Medical Genetics and Genomics guidelines recommends before testing, patients meet with a genetic counselor for assessing suitability for genetic testing. 4 The introduction of next-generation sequencing has revolutionized molecular diagnostics with a multiplex testing approach that is both time and cost effective. Compared with sequential single-gene testing, panel testing offers an expedited evaluation of multiple genes and can result in a higher identification rate of germline alterations. 5 Furthermore, panel testing allows an evaluation of hereditary syndromes that may not be discernable by clinical diagnosis. The American Society of Clinical Oncology has recognized panel testing for high-penetrance genes of established clinical utility, provided that patients receive education and provide pretest consent. 6 The clinical utility of panel tests in the diagnosis of hereditary breast, ovarian, and colorectal cancers has been described [7] [8] [9] but has yet to be reported for hereditary kidney cancer.
MATERIALS AND METHODS

Patient Cohort
We retrospectively reviewed de-identified data from patients with a personal diagnosis of kidney cancer who underwent panel testing targeted for hereditary kidney cancer (RenalNext) at a commercial diagnostic laboratory (Ambry Genetics, Aliso Viejo, California) from August 2013 through June 2016. Patient information was recorded from the requisition form and included sex, ethnicity/race, age of cancer diagnosis, tumor histology, history of a secondary cancer, family history of cancer, ordering provider institution type, and ordering provider specialty. Clinical characteristics, including kidney cancer histology, personal history, and family history, were reviewed for mutation carriers to examine consistency with described features of the respective kidney cancer syndrome. All patients with RCC histology were reviewed, including those who had gene alterations associated with Lynch syndrome, because some investigators have reported a possible association with nonurothelial renal malignancies. [10] [11] [12] Multigene Panel Testing [TP53] , TSC1, TSC2, and VHL) currently implicated in syndromes associated with kidney cancer. Genomic DNA was isolated from a blood or saliva sample and then quantified (Nanodrop; Thermo Scientific, Pittsburgh, Pennsylvania; or Infinite F200; Tecan, San Jose, California). Sequence enrichment was performed by incorporating genomic DNA onto a microfluidics chip or into microdroplets with primer pairs or by a bait-capture methodology using long biotinylated oligonucleotide probes (RainDance Technologies, Billerica, Massachusetts; or Integrated DNA Technologies, San Diego, California). This procedure was then followed by next-generation sequencing analysis (Illumina, San Diego, California) of all coding exons in addition to least 5 bases into the 5 0 and 3 0 ends of all introns except for MITF and EPCAM. Sequencing of specific promoter regions was performed if they were associated with pathogenic alterations. 13 For MITF, only the p.E318K alteration was analyzed, because this is the only known alteration associated with RCC. [14] [15] [16] For EPCAM, only large deletions that have been associated with cancer predisposition were evaluated. 17 Sanger sequencing was performed to confirm variant calls other than known nonpathogenic alterations and for any regions missing or with insufficient read depth coverage for variant detection.
A targeted chromosomal microarray designed with increased probe density in regions of interest was used for the detection of gross deletions and duplications (Aglient, Santa Clara, California). Gross deletion/duplication analysis of PMS2 was performed using MLPA Kit P008-B1 (MRC-Holland, Amsterdam, the Netherlands). If a deletion was detected in select exons (13, 14, or 15 and, in some cases, 12) of PMS2, then double-stranded sequencing of the appropriate exon(s) of the PMS2 C-terminal like pseudogene (PMS2CL) was performed to determine whether the deletion was located in the PMS2 gene or the pseudogene. Interpretation of sequence variations was classified according to the American College of Medical Genetics and Genomics guidelines. 18 Variants were classified as pathogenic, likely pathogenic (positive test), variant of unknown significance (VUS), likely benign, or benign according to the Ambry 5-tier variant classification protocol. 19 For patients who had positive RenalNext results, when available, detailed personal and family history provided was reviewed to determine whether there was high clinical suspicion before testing.
Statistical Analysis
The Student t test was used to compare differences in age distributions between the testing population and US RCC population obtained from the Surveillance, Epidemiology,
Original Article
and End Results-17 Registries database, as previously described. 1 All tests were 2-tailed, and statistical significance considered if P .05. A logistic regression analysis was performed to evaluate predictors of a positive panel test. All statistical analyses and figures were generated with JMP 11.2.1 statistical software (SAS Institute Inc, Cary, North Carolina).
RESULTS
In total, 1235 patients with RCC underwent RenalNext testing (Table 1 ). An increase in RenalNext use was observed during the study period, because the average numbers of tests ordered per month were 12, 34.4, 45.6, and 40.5 for the years 2013, 2014, 2015, and 2016, respectively. Although diverse ethnicities were represented, Caucasian individuals constituted the majority of the cohort being studied (64.1%). The majority of patients who were referred for genetic testing were men (53.9%), which was less than expected based on patients with kidney cancer in the literature (P < .0001). 20 In a comparison of normalized age distributions, patients with kidney cancer who were referred for genetic testing had a mean 6 standard deviation age at diagnosis of 46.2 6 13.7 years, which was younger than the US population of patients with kidney cancer, who had a mean 6 standard deviation age at diagnosis of 63.2 6 13.3 years (P < .0001) (Fig. 1) . Histology was reported for 942 patients (76.3%). Of 686 patients who reported common kidney tumor histology, 459 (66.9%), 145 (21.1%), and 82 (12.1%) had clear cell, papillary, and chromophobe kidney tumors, respectively. This histologic distribution differed significantly from what is described in the literature for kidney cancer (P < .0001). 21 The remaining 256 patients reported less common or mixed histology. In total, 859 patients (69.6%) had only kidney cancer, 283 (22.9%) had an additional primary cancer, and 93 (7.5%) had 2 primary cancers. In total, 1007 patients (81.5%) reported a family history of cancer, and 369 (29.9%) reported a family member with kidney cancer. Upon examination of institutional referral patterns, university hospitals/academic cancer centers represented 623 cases (50.4%), nonuniversity hospitals represented 545 cases (44.1%), private practice providers represented 56 cases (4.5%), and other providers represented 11 cases (0.9%). For specialists ordering a panel test, genetics providers referred 995 cases (80.6%), medical oncology physicians referred 169 cases (13.7%), nononcology physicians referred 13 cases (1.1%), and other health care providers referred 58 cases (4.7%).
Of those who were evaluated with the RenalNext panel, 6.1% had a positive test, 18.4% had a VUS, and 75.5% received a negative result. Mutations were identified in 15 of the genes evaluated with RenalNext (Fig.  2B) . FLCN, FH, MITF, and SDHB had the highest positive rates at 1.8%, 1.3%, 0.7%, and 0.6%, respectively. BAP1, MET, SDHA, TSC2, and VHL all had positive rates of 0.2%. One or more VUS was identified in 17 of the 19 genes in the panel (Fig. 2C) . TSC2, MET, and PMS2 had the highest VUS rates at 2.7%, 2.2%, and 1.7%, respectively. Of the patients who received an inconclusive result (18.4%), the majority had only 1 VUS (91.1%); however, some patients had 2 or more (8.9%) ( Fig. 2A) . On multivariate logistic regression, earlier age of onset was identified as predictive of a positive panel test with an odds ratio of 0.975 (95% confidence interval, 0.958-0.993; P 5 .0052) ( Table 2) . A personal history of a second cancer or a family history of kidney cancer was not identified as a meaningful predictor of a positive test. Overall, 18 of 32 patients (56.3%) with available submitted histology were consistent with published literature based on the specific gene alteration. For patients who provided sufficient personal and family history, only 23 of 70 (32.9%) had a strong suspicion for the noted gene alteration (Table 3) . The majority of patients with MITF (c.952G>A), FH, and FLCN mutations were Caucasian. The age of onset was younger than that in the US population of patients with kidney cancer, at a median ranging from 32.5 years (for FH) to 51 years (for FLCN). For MITF-associated kidney cancer, histology has not been well characterized; for tumors associated with this condition, clear cell and papillary histologies were most often reported. The associations with other cancers differed by germline mutation, as expected. The majority of patients with FH and MITF mutations did not have a second primary (75% and 77.8%, respectively), whereas a significant proportion of individuals with FLCN had at least 1 additional primary (45.5%). The majority of patients (66.7%) who had an MITF mutation identified did not have a family history of kidney cancer.
DISCUSSION
We report results from the first hereditary kidney cancer panel test, RenalNext, which provides important information to clinicians regarding the expectations of detecting pathogenic alterations. In our cohort, the overall detection rate was 6.1% for pathologic variants, which is comparable to the rates described by other panel tests for breast and colorectal cancers. 8, 9 Because single gene testing remains available for more commonly recognized and prevalent syndromes (such as VHL), differences in testing patterns can influence specific variant detection on panel testing. In addition, it is anticipated that the testing of patients who have low-risk features will have a lower yield and may not justify the costs and associated uncertainty/ risks of testing.
Advances in sequencing technology have led to a reduction in costs, allowing for incorporation of multiple genes onto a single panel test. 22 Because of a breadth of possible histologies associated with some syndromes, such as Birt-Hogg-Dube syndrome, hereditary leiomyomatosis and RCC, or MITF-associated RCC, a definitive diagnosis may have been missed if single gene testing had been used. In some syndromes, overlapping phenotypes were observed in mutation carriers, making it a challenge to select 1 or 2 appropriate genes for testing. For instance, we identified variable histologies in multiple hereditary kidney cancer syndromes, such as succinate dehydrogenase-deficient kidney cancer, tuberous sclerosis complex, and Cowden syndrome. We also observed that just over one-half of patients had a type of kidney cancer known to be associated with the respective gene, and only one-third reported characteristics suspicious for the respective gene. This observation may because in part by under-reporting of syndromic characteristics on test requisition forms as well as incidental detection of alterations not causally linked to tumorigenesis. Furthermore, these inconsistencies may be attributed to the inherent challenges of recognizing rare syndromes and/or the lack of appropriate clinical examination for subtle characteristics. In these particular patients, multigene panel testing offers clear clinical utility. With a larger screening pool of genes, there is a higher detection rate for germline alterations compared with single gene testing. 5 Because panel tests have been recently introduced, they may present unforeseen challenges, such as discordant disease characteristics. We may soon learn that the phenotypic spectra of RCC syndromes are broader than initially understood. 9 Thus, as more genes are incorporated into panels, there is inevitably a higher percentage of VUS. Problems may arise when clinicians over-interpret a VUS as a pathogenic mutation and provide excess medical intervention. 23 We observed that, with the RenalNext panel, 18.4% of patients in the cohort had at least 1 VUS in the absence of a pathogenic mutation. The highest prevalence of VUS stemmed from TSC2, MET, and PMS2, with rates of 2.7%, 2.2%, and 1.7%, respectively. Continued investigation of hereditary kidney cancer panel results from larger cohorts will aid in optimization of these panels to maximize positive identification rates and minimize VUS rates. With a growing body of genotypephenotype data and continued improvement in the methods used to assess the pathogenicity of variants, the frequency of VUS with genetic testing may decrease over time.
For MITF-associated kidney cancer, we observed that patients often do not have any family history of kidney cancer. Although these individuals could have a de novo gene alteration, the more likely explanation is that kidney cancer represents a low-penetrance disease manifestation. Therefore, it is important for clinicians to be aware that, when encountering these patients, familial history may not be as suggestive as with other classic syndromes like VHL or HPRC.
For many hereditary cancer syndromes, there often is a wide racial distribution. Of patients with a known ethnicity in this cohort, the majority were Caucasian (86%), which may represent a founder effect or could be related to racial/ethnic patterns of referral for genetic testing. Finally, whereas some conditions like HPRC and VHL have an established histologic phenotype associated with renal tumors, we report that patients with the MITF p.E318K alteration presented with a wide distribution of kidney tumors that included both clear cell and papillary type histology. With the inability to rely on a specific type of cancer and the lack of family history, clinicians have limited clues to suspect a genetic form of kidney cancer. Early age of onset was observed in both MITF and BAP1 syndromes. The inclusion of such genes in a kidney cancer panel is useful for detection, because there are limited distinguishing clinical characteristics that would allow selection for single gene testing.
The inclusion of large numbers of genes has raised concerns over the high frequency of indeterminate results with panel testing. 24 An important role for the clinician is to identify patients who would be good candidates for germline testing. Age guidelines for referral for genetic counseling have been proposed for patients with kidney cancer, because studies have indicated that RCC syndromes are associated with an earlier age of cancer onset. 1, 25 Consistent with these guidelines, we demonstrate that individuals undergoing genetic testing were significantly younger than the overall US population of patients with kidney cancer. We also observed that, among those who underwent panel testing, the age of onset, and not a personal/family history of cancer, was a significant predictor of a positive test. This reinforces the significance of age for selecting appropriate patients for counseling and/or testing. Whereas clinicians may have limited experience with the diagnostic criteria and referral guidelines for these rare syndromes, age alone is a very discernible feature that requires no specific training to recognize.
Although our study is strengthened by the use of a large cohort that includes a variety of hereditary kidney cancer syndromes, we recognize its limitations. Whereas this is the first panel test designed for kidney cancer, other genotype-phenotype correlations must be interpreted with caution. Although this study primarily examined individuals who were suspected to have a hereditary kidney cancer syndrome, the results may not be generalizable to all patients with kidney cancer patients. Our cohort also included several individuals with alterations in Lynch syndrome genes who developed RCC. The association with nonurothelial renal tumors is currently under investigation; thus, it is possible that such tumors developed independent of the germline alteration. The downstream consequences of detecting a germline alteration cannot be assessed in this type of study; however, a prospective trial is planned to address how testing impacts clinical management and cascade genetic screening.
Conclusions
The landscape of genetic testing has shifted toward the use of multigene panel tests. Patients with family history, unique personal history, and early onset of kidney cancer are those who may benefit from genetic testing. Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes.
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